Dermatol. praxi. 2024;18(4):178-184 | DOI: 10.36290/der.2024.035
Primary cutaneous T-cell lymphomas - new therapeutical options
- I. dermatovenerologická klinika, FN u sv. Anny v Brně a LF MU, Brno
- Masarykův onkologický ústav, Brno
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL). Sézary syndrome (SS) is a rare leukemic variant of CTCL. MF has a long course and is not easy to diagnose in the initial stages of the disease. Diagnosis at an early stage and initiation of therapy will increase the likelihood of achieving and maintaining a long-term disease free interval. Both in the treatment of MF and for patients with SS, we now have new therapeutic options that may prolong their overall survival.
Keywords: mycosis fungoides, Sézary syndrome, diagnostics, therapy,
Accepted: November 6, 2024; Published: November 22, 2024 Show citation
PDF will be unlocked 22.11.2025 |
References
- Willemze R. Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification. Presse Med. 2022;51:104126.
Go to original source... 
Go to PubMed... - Primary Cutaneous Lymphoma, Version 1.2023. NCCN clinical practice guidelines in oncology, national comprehensive cancer network, 2023. Retrieved March 2023. Available from: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf.
- Beyer M, Möbs M, Humme D, et al. Pathogenesis of Mycosis fungoides. J Dtsch Dermatol Ges. 2011 Aug;9(8):594-8. Go to original source... Go to PubMed...
- Beyer M, Sterry W. Cutaneous Lymphoma. In Goldsmith LA, Katz SI, Gilchrest BA, et al. Fitzpatrick's Dermatology in General Medicine, 8th Ed. New York: McGraw-Hill Companies Inc.; 2012:1745-1766.
- Kempf W, Zimmermann AK, Mitteldorf C, et al. Cutaneous Lymphomas - An update 2019. Hematological Oncology. 2019 Jun;37 Suppl 1:43-47. doi: 10.1002/hon.2584. PMID: 31187534. Go to original source... Go to PubMed...
- Willemze R, Hodak E, Zinzani PL, et al. ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40. Go to original source... Go to PubMed...
- Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cacer (EORTC). Blood. 2007;110:1713-22. Go to original source... Go to PubMed...
- Latzka J, Assaf CH, Bagot M, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - update 2023. Eur J Cancer. 2023;195:113343. Go to original source... Go to PubMed...
- Belada D, Trněný M. Diagnostické a léčebné postupy u nemocných s maligními lymfomy - XIV. vydání [cited 2024 Sep 20]. Available from: https://www.lymphoma.cz.
- SPC Ledaga (chlormethine). Available from: www.sukl.cz.
- Šlampa P, et al. Radiační onkologie v praxi. 5. aktualizované vydání, Brno: Masarykův onkologický ústav; 2023.
- Fialová P, Vašků V, Adam Z. Naše zkušenosti s léčbou bexarotenem u kožních T-lymfomů. Dermatol. praxi. 2011;5(4):187-191.
- Polívka J. Mogamulizumab: nová léčba pokročilých stadií kožních T buněčných lymfomů-mycosis fungoides a Sézaryho syndromu. Onkologie. 2021;15(4):187-193. Go to original source...
- Belada D. Brentuximab vedotin v léčbě relabujících CD30+ kožních lymfomů - výsledky mezinárodní randomizované klinické studie fáze 3-ALCANZA. Onkologie. 2018;12(3):123-127. Go to original source...
- Ettler J, Polívka J, Arenberger P. Primární kožní lymfomy v dermatologické praxi. Dermatol. praxi. 2018;12(3):128-132. Go to original source...